Novel amides of mycophenolic acid and some heterocyclic derivatives as immunosuppressive agents

References

• Hedstrom L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009;109(7):2903–28.
   PubMed Web of Science ®Google Scholar
• Sintchak MD, Fleming MA, Futer O, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell. 1996;85(6):921–30.
   PubMed Web of Science ®Google Scholar
• Yuan S, Gopal JV, Ren S, Chen L, Liu L, Gao Z. Anticancer fungal natural products: mechanisms of action and biosynthesis. Eur J Med Chem. 2020;202:112502.
   PubMed Web of Science ®Google Scholar
• Bentley R. Mycophenolic Acid: a one hundred year odyssey from antibiotic to immunosuppressant. Chem Rev. 2000;100(10):3801–26.
   PubMed Web of Science ®Google Scholar
• Wagner M, Earley AK, Webster AC, et al. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015;3(12):CD007746.
   PubMed Web of Science ®Google Scholar
• Sahman M, Mugosa S, Rancic N. Utilization of mycophenolic acid, azathioprine, tacrolimus, cyclosporin, sirolimus, and everolimus: multinational study. Front Public Health. 2021;9:671316.
   PubMed Web of Science ®Google Scholar
• Song X, Tu R, Mei X, Wu S, Lan B, Zhang L, Luo X, Liu J, Luo M. A mycophenolic acid derivative from the fungus penicillium sp. SCSIO sof101. Nat Prod Res. 2020;34(9):1206–12.
   PubMed Web of Science ®Google Scholar
• Pilevneli AD, Ebada SS, Kaşkatepe B, Konuklugil B. Penicacids H–J, three new mycophenolic acid derivatives from the marine-derived fungus Rhizopus oryzae. RSC Adv. 2021;11(55):34938–44.
   PubMed Web of Science ®Google Scholar
• Klangjorhor J, Chaiyawat P, Teeyakasem P, Sirikaew N, Phanphaisarn A, Settakorn J, Lirdprapamongkol K, Yama S, Svasti J, Pruksakorn D. Mycophenolic acid is a drug with the potential to be repurposed for suppressing tumor growth and metastasis in osteosarcoma treatment. Int J Cancer. 2020;146(12):3397–409.
   PubMed Web of Science ®Google Scholar
• Hirunsatitpron P, Hanprasertpong N, Noppakun K, Pruksakorn D, Teekachunhatean S, Koonrungsesomboon N. Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(2):476–89.
   PubMed Web of Science ®Google Scholar
• Benjanuwattra J, Chaiyawat P, Pruksakorn D, Koonrungsesomboon N. Therapeutic potential and molecular mechanism of mycophenolic acid as an anticancer agents. Eur J Pharmacol. 2020;887:173580.
   PubMed Web of Science ®Google Scholar
• Cholewinski G, Malachowska-Ugarte M, Dzierzbicka K. The chemistry of mycophenolic acid - synthesis and modifications towards desired biological activity. Curr Med Chem. 2010;17(18):1926–41.
   PubMed Web of Science ®Google Scholar
• Lee S, Ku AF, Vippila MR, Wang Y, Zhang M, Wang X, Hedstrom L, Cuny GD. Mycophenolic anilides as broad specificity inosine-5’-monophosphate dehydrogenase (IMPDH) inhibitors. Bioorg Med Chem Lett. 2020;30(24):127543.
   PubMed Web of Science ®Google Scholar
• Batovska DI, Kim DH, Mitsuhashi S, Cho YS, Kwon HJ, Ubukata M. Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level. Biosci Biotechnol Biochem. 2008;72(10):2623–31.
   PubMed Web of Science ®Google Scholar
• Sunohara K, Mitsuhashi S, Shigetomi K, Ubukata M. Discovery of N-(2,3,5-triazoyl)mycophenolic amide and mycophenolic epoxyketone as novel inhibitors of human IMPDH. Bioorg Med Chem Lett. 2013;23(18):5140–44.
   PubMed Web of Science ®Google Scholar
• Peng Y, Dong Y, Mahato RI. Synthesis and characterization of a novel mycophenolic acid–quinic acid conjugate serving as immunosuppressant with decreased toxicity. Mol Pharm. 2015;12(12):4445–53.
   PubMedGoogle Scholar
• Felczak K, Vince R, Pankiewicz KW. NAD-based inhibitors with anticancer potential. Bioorg Med Chem Lett. 2014;24(1):332–6.
   PubMed Web of Science ®Google Scholar
• Siebert A, Wysocka M, Krawczyk B, Cholewiński G, Rachoń J. Synthesis and antimicrobial activity of amino acid and peptide derivatives of mycophenolic acid. Eur J Med Chem. 2018;143:646–55.
   PubMed Web of Science ®Google Scholar
• Shah CP, Kharkar PS. Newer human inosine 5′-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents. J Enzyme Inhib Med Chem. 2018;33(1):972–7.
   PubMed Web of Science ®Google Scholar
• Shang FF, Wang MY, Ai JP, Shen QK, Guo HY, Jin CM, Chen FE, Quan ZS, Jin L, Zhang C. Synthesis and evaluation of mycophenolic acid derivatives as potential antiToxoplasma gondii agents. Med Chem Res. 2021;30(12):2228–39.
   Web of Science ®Google Scholar
• Juvale K, Shaik A, Kirubakaran S. Inhibitors of inosine 5′-monophosphate dehydrogenase as emerging new generation antimicrobial agents. Medchemcomm. 2019;10(8):1290–301.
   PubMed Web of Science ®Google Scholar
• Shah CP, Kharkar PS. Discovery of novel human inosine 5,-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents. Eur J Med Chem. 2018;158:286–301.
   PubMed Web of Science ®Google Scholar
• Cholewiński G, Iwaszkiewicz-Grześ D, Prejs M, Głowacka A, Dzierzbicka K. Synthesis of the inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors. J Enzyme Inhib Med Chem. 2015;30(4):550–63.
   PubMed Web of Science ®Google Scholar
• Martins P, Jesus J, Santos S, Raposo LR, Roma-Rodrigues C, Baptista PV, Fernandes AR. Heterocyclic anticancer compounds: recent advances and the paradigm shift towards the use of nanomedicine’s tool box. Molecules. 2015;20(9):16852–91.
   PubMed Web of Science ®Google Scholar
• Vitaku E, Smith DT, Njardarson JT. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J Med Chem. 2014;57(24):10257–74.
   PubMed Web of Science ®Google Scholar
• Gorla SK, Kavitha M, Zhang M, Chin JEW, Liu X, Striepen B, Makowska-Grzyska M, Kim Y, Joachimiak A, Hedstrom L, et al. Optimization of benzoxazole-based inhibitors of cryptosporidium parvum Inosine 5′-monophosphate dehydrogenase. J Med Chem. 2013;56(10):4028–43.
   PubMed Web of Science ®Google Scholar
• Paramashivappa R, Phani Kumar P, Subba Rao PV, Srinivasa Rao A. Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2003;13(4):657–60.
   PubMed Web of Science ®Google Scholar
• Ghorab M, Bashandy M, Alsaid M. Novel thiophene derivatives with sulfonamide, isoxazole, benzothiazole, quinoline and anthracene moieties as potential anticancer agents. Acta Pharm. 2014;64(4):419–31.
   PubMed Web of Science ®Google Scholar
• Husain A, Rashid M, Shaharyar M, Siddiqui AA, Mishra R. Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines: new anticancer agents. Eur J Med Chem. 2013;62:785–98.
   PubMed Web of Science ®Google Scholar
• Golden EB, Cho H-Y, Hofman FM, Louie SG, Schönthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12.
   PubMed Web of Science ®Google Scholar
• Volochnyuk D, Grygorenko O, Gorlova A. Fluorine-containing diazines in medicinal chemistry and agrochemistry. J Fluor Chem. 2014;2:577–672.
   Google Scholar
• Irfan A, Batool F, Zahra Naqvi SA, Islam A, Osman SM, Nocentini A, Alissa SA, Supuran CT. Benzothiazole derivatives as anticancer agents. J Enzyme Inhib Med Chem. 2020;35(1):265–79.
   PubMed Web of Science ®Google Scholar
• Abrol S, Bodla RB, Goswani C. A comprehensive review on benzothiazole derivatives for their biological activities. Int J Pharm Sci Res. 2019;10:3196–209.
   Web of Science ®Google Scholar
• El-Faham A, Albericio F. Peptide coupling reagents, more than a letter soup. Chem Rev. 2011;111(11):6557–602.
   PubMed Web of Science ®Google Scholar
• Carpino LA, Ionescu D, El-Faham A. Peptide coupling in the presence of highly hindered tertiary amines. J Org Chem. 1996;61(7):2460–65.
   Web of Science ®Google Scholar
• Beyermann M, Henklein P, Klose A, Sohr R, Bienert M. Effect of tertiary amine on the carbodiimide-mediated peptide synthesis. Int J Pept Protein Res. 1991;37(4):252–6.
   PubMedGoogle Scholar
• Jain A, Yang G, Yalkowsky SH. Estimation of melting points of organic compounds. Ind Eng Chem Res. 2004;43(23):7618–21.
   Web of Science ®Google Scholar
• Larina LI. Tautomerism and structure of azoles: nuclear magnetic resonance spectroscopy. Adv Heterocycl Chem. 2018;124:233–321.
   Web of Science ®Google Scholar
• Sawhney SN, Boykin DW. Transmission of substituent effects in heterocyclic systems by carbon-13 nuclear magnetic resonance Benzothiazoles. J Org Chem. 1979;44(7):1136–42.
   Web of Science ®Google Scholar
• Cholewinski G, Iwaszkiewicz-Grzes D, Trzonkowski P, Dzierzbicka K. Synthesis and biological activity of ester derivatives of mycophenolic acid and acridines/acridones as potential immunosuppressive agents. J Enzyme Inhib Med Chem. 2016;31(6):974–82.
   PubMed Web of Science ®Google Scholar
• Prejs M, Cholewiński G, Trzonkowski P, Kot-Wasik A, Dzierzbicka K. Synthesis and antiproliferative activity of new mycophenolic acid conjugates with adenosine derivatives. J Asian Nat Prod Res. 2019;21(2):178–85.
   PubMed Web of Science ®Google Scholar
• Siebert A, Cholewiński G, Trzonkowski P, Rachon J. Immunosuppressive properties of amino acid and peptide derivatives of mycophenolic acid. Eur J Med Chem. 2020;189:112091.
   PubMed Web of Science ®Google Scholar
• Ten Brinke A, Marek-Trzonkowska N, Mansilla MJ, et al. Monitoring T-cell responses in translational studies: optimization of dye-based proliferation assay for evaluation of antigen-specific responses. Front Immunol. 2017;8:1870.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi S, Takenaka J, Iwamori K, Nakajima N, Ubukata M. Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycophenolic acid derivatives. Bioorg Med Chem. 2010;18(22):8106–11.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hisakawa S, Itoh Y, Suzuki N, Takahashi K, Kawahata M, Yamaguchi K, Nakagawa H, Miyata N. Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007;17(15):4208–12.
   PubMed Web of Science ®Google Scholar
• Park H, Kim S, Kim YE, Lim SJ. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups. ChemMedChem. 2010;5(4):591–7.
   PubMed Web of Science ®Google Scholar
• Tung TT, Oanh DTK, Dung PTP, Hue VTM, Park SH, Han BW, Kim Y, Hong J-T, Han S-B, Nam NH, et al. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents. Med Chem. 2013;9(8):1051–7.
   PubMed Web of Science ®Google Scholar
• HyperChem(TM) Professional 7.51, 1115 NW 4th Street. Gainesville (FL): Hypercube, Inc. https://hyperchem.software.informer.com/. [accessed 1 May 2022].
   Google Scholar
• Hocquet A, Langgård M. An evaluation of the MM + force field. J Mol Model. 1998;4(3):94–112.
   Web of Science ®Google Scholar
• Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14(1):33–8, 27–8.
   PubMedGoogle Scholar
• Iwaszkiewicz-Grzes D, Cholewinski G, Kot-Wasik A, Trzonkowski P, Dzierzbicka K. Investigations on the immunosuppressive activity of derivatives of mycophenolic acid in immature dendritic cells. Int Immunopharmacol. 2017;44:137–42.
   PubMed Web of Science ®Google Scholar